Cited by 1,486HIV Research and TreatmentRNA regulation and diseaseHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

Open access

Mangeat, Bastien, Turelli, Priscilla, Caron, Gersende, Friedli, Marc, Perrin, Luc, Trono, Didier·2003·Nature

Open this paper in CoChat — free account

Abstract

Viral replication usually requires that innate intracellular lines of defence be overcome, a task usually accomplished by specialized viral gene products. The virion infectivity factor (Vif) protein of human immunodeficiency virus (HIV) is required during the late stages of viral production to counter the antiviral activity of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a protein expressed notably in human T lymphocytes. When produced in the presence of APOBEC3G, vif-defective virus is non-infectious. APOBEC3G is closely related to APOBEC1, the central component of an RNA-editing complex that deaminates a cytosine residue in apoB messenger RNA. APOBEC family members also have potent DNA mutator activity through dC deamination; however, whether the editing potential of APOBEC3G has any relevance to HIV inhibition is unknown. Here, we demonstrate that it does, as APOBEC3G exerts its antiviral effect during reverse transcription to trigger G-to-A hypermutation in the nascent retroviral DNA. We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens.

Integrity signals

Registry

Crossref · 10.1038/nature01709

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
Sheehy, A. M., Gaddis, N., Choi, J. D., & Malim, M. H. (2002) · Nature · doi:10.1038/nature00939 · Cited by 2,407
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Self-citation
A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine
Powell, L. M., Wallis, S. C., Pease, R. J., Edwards, Y. H., Knott, T. J., & Scott, J. (1987) · Cell · doi:10.1016/0092-8674(87)90510-1 · Cited by 1,039
Transcription-targeted DNA deamination by the AID antibody diversification enzyme
Chaudhuri, J., Tian, M., Khuong, C., Chua, K. F., Pinaud, E., & Alt, F. W. (2003) · Nature · doi:10.1038/nature01574 · Cited by 746
An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22
Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., & Navaratnam, N. (2002) · Genomics · doi:10.1006/geno.2002.6718 · Cited by 711
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 695
RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators
Harris, R. S., Petersen‐Mahrt, S. K., & Neuberger, M. S. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00742-6 · Cited by 609
Molecular Cloning of an Apolipoprotein B Messenger RNA Editing Protein
Teng, B., Burant, C. F., & Davidson, N. O. (1993) · Science · doi:10.1126/science.8511591 · Cited by 536
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes
Gabuzda, D. H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W. A., & Sodroski, J. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6489-6495.1992 · Cited by 444
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells
von Schwedler, U. K., Song, J., Aiken, C., & Trono, D. (1993) · Journal of Virology · doi:10.1128/jvi.67.8.4945-4955.1993 · Cited by 441
Self-citation

Show all 28 references

Sorted by citations

Rates of evolutionary change in viruses: patterns and determinants
Duffy, S., Shackelton, L. A., & Holmes, E. C. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2323 · Cited by 1,605
Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex
Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., & Yu, X.-F. (2003) · Science · doi:10.1126/science.1089591 · Cited by 1,194
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,225
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
Sheehy, A. M., Gaddis, N., & Malim, M. H. (2003) · Nature Medicine · doi:10.1038/nm945 · Cited by 961
Mechanisms of viral mutation
Sanjuán, R., & Domingo‐Calap, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2299-6 · Cited by 995
Quasispecies Theory and the Behavior of RNA Viruses
Lauring, A. S., & Andino, R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001005 · Cited by 888
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
Marin, M., Rose, K. M., Kozak, S. L., & Kabat, D. (2003) · Nature Medicine · doi:10.1038/nm946 · Cited by 794
HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability
Stopak, K., de Noronha, C. M. C., Yonemoto, W. M., & Greene, W. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00353-8 · Cited by 723
Retroviral restriction by APOBEC proteins
Harris, R. S., & Liddament, M. T. (2004) · Nature reviews. Immunology · doi:10.1038/nri1489 · Cited by 657
Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins
Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S., & Malim, M. H. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.057 · Cited by 613
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome
Yu, Q., König, R., Pillai, S. K., Chiles, K., Kearney, M. F., Palmer, S., Richman, D., Coffin, J. M., & Landau, N. R. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb758 · Cited by 596
The AID/APOBEC family of nucleic acid mutators
Conticello, S. G. (2008) · Genome biology · doi:10.1186/gb-2008-9-6-229 · Cited by 544
Intrinsic antiviral immunity
Yan, N., & Chen, Z. J. (2012) · Nature Immunology · doi:10.1038/ni.2229 · Cited by 565
APOBECs and virus restriction
Harris, R. S., & Dudley, J. P. (2015) · Virology · doi:10.1016/j.virol.2015.03.012 · Cited by 551
HIV-1 Reverse TranscriptionPreprint
Hu, W.-S., & Hughes, S. H. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006882 · Cited by 597
Evolution of the AID/APOBEC Family of Polynucleotide (Deoxy)cytidine Deaminases
Conticello, S. G., Thomas, C. J. F., Petersen‐Mahrt, S. K., & Neuberger, M. S. (2004) · Molecular Biology and Evolution · doi:10.1093/molbev/msi026 · Cited by 489
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G
Sawyer, S. L., Emerman, M., & Malik, H. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020275 · Cited by 485
Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity
Newman, E. N. C., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H., & Sheehy, A. M. (2005) · Current Biology · doi:10.1016/j.cub.2004.12.068 · Cited by 480
HIV Restriction Factors and Mechanisms of EvasionPreprint
Malim, M. H., & Bieniasz, P. D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006940 · Cited by 517
Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway
Mehle, A., Strack, B., Ancuța, P., Zhang, C., McPike, M. P., & Gabuzda, D. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313093200 · Cited by 485
The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G
Conticello, S. G., Harris, R. S., & Neuberger, M. S. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.034 · Cited by 468
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins
Wiegand, H. L., Doehle, B., Bogerd, H. P., & Cullen, B. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600246 · Cited by 466
Intrinsic immunity: a front-line defense against viral attack
Bieniasz, P. D. (2004) · Nature Immunology · doi:10.1038/ni1125 · Cited by 450
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells
Chiu, Y., Soros, V. B., Kreisberg, J. F., Stopak, K., Yonemoto, W. M., & Greene, W. C. (2005) · Nature · doi:10.1038/nature03493 · Cited by 437
Retracted
APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo
Liddament, M. T., Brown, W. L., Schumacher, A. J., & Harris, R. S. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.050 · Cited by 437
Inhibition of Hepatitis B Virus Replication by APOBEC3G
Turelli, P., Mangeat, B., Jost, S., Vianin, S., & Trono, D. (2004) · Science · doi:10.1126/science.1092066 · Cited by 432
Self-citation
Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication
Zheng, Y., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., & Peterlin, B. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.6073-6076.2004 · Cited by 430
The structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 499
The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements
Chiu, Y., & Greene, W. C. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090350 · Cited by 426
APOBEC3A Is a Potent Inhibitor of Adeno-Associated Virus and Retrotransposons
Chen, H., Lilley, C. E., Yu, Q., Lee, D. V., Chou, J., Narvaiza, I., Landau, N. R., & Weitzman, M. D. (2006) · Current Biology · doi:10.1016/j.cub.2006.01.031 · Cited by 385
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition
Bogerd, H. P., Wiegand, H. L., Hulme, A. E., Garcia-Perez, J. L., O’Shea, K., Moran, J. V., & Cullen, B. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603313103 · Cited by 372
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α
Hatziioannou, T., Pérez-Caballero, D., Yang, A., Cowan, S., & Bieniasz, P. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402361101 · Cited by 371
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction
Refsland, E. W., Stenglein, M. D., Shindo, K., Albin, J. S., Brown, W. L., & Harris, R. S. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq174 · Cited by 369
The role of mutational robustness in RNA virus evolution
Lauring, A. S., Frydman, J., & Andino, R. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3003 · Cited by 368
APOBEC3 Proteins Inhibit Human LINE-1 Retrotransposition
Muckenfuß, H., Hamdorf, M., Held, U., Perković, M., Löwer, J., Cichutek, K., Flory, E., Schumann, G. G., & Münk, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601716200 · Cited by 366
The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities
Keckesova, Z., Ylinen, L. M. J., & Towers, G. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402474101 · Cited by 342
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses
Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., Hance, A. J., Heidmann, T., & Schwartz, O. (2005) · Nature · doi:10.1038/nature03238 · Cited by 341
HIV-1 Vif, APOBEC, and Intrinsic Immunity
Goila-Gaur, R., & Strebel, K. (2008) · Retrovirology · doi:10.1186/1742-4690-5-51 · Cited by 341
APOBEC-Mediated Cytosine Deamination Links PIK3CA Helical Domain Mutations to Human Papillomavirus-Driven Tumor Development
Henderson, S. R., Chakravarthy, A., Su, X., Boshoff, C., & Fenton, T. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.012 · Cited by 345
Animal models for HIV/AIDS research
Hatziioannou, T., & Evans, D. T. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2911 · Cited by 378
Comparison of the Differential Context-dependence of DNA Deamination by APOBEC Enzymes: Correlation with Mutation Spectra in Vivo
Beale, R. C. L., Petersen‐Mahrt, S. K., Watt, I. N., Harris, R. S., Rada, C. A., & Neuberger, M. S. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.046 · Cited by 340
Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets
Koning, F. A., Newman, E. N. C., Kim, E., Kunstman, K., Wolinsky, S. M., & Malim, M. H. (2009) · Journal of Virology · doi:10.1128/jvi.01089-09 · Cited by 334
Evidence for Editing of Human Papillomavirus DNA by APOBEC3 in Benign and Precancerous Lesions
Vartanian, J., Guétard, D., Henry, M., & Wain–Hobson, S. (2008) · Science · doi:10.1126/science.1153201 · Cited by 327
APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts
Bishop, K. N., Verma, M., Kim, E., Wolinsky, S. M., & Malim, M. H. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000231 · Cited by 326
APOBEC3 proteins mediate the clearance of foreign DNA from human cells
Stenglein, M. D., Burns, M. B., Li, M., Lengyel, J., & Harris, R. S. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1744 · Cited by 339
Cellular Proteins in Influenza Virus Particles
Shaw, M. L., Stone, K. L., Colangelo, C. M., Gulcicek, E. E., & Palese, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000085 · Cited by 324
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G
Iwatani, Y., Chan, D., Wang, F., Stewart-Maynard, K. M., Sugiura, W., Gronenborn, A. M., Rouzina, I. F., Williams, M. C., Musier‐Forsyth, K., & Levin, J. G. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm750 · Cited by 321
DNA precursor metabolism and genomic stability
Mathews, C. K. (2006) · The FASEB Journal · doi:10.1096/fj.06-5730rev · Cited by 311
Reconstitution of an Infectious Human Endogenous Retrovirus
Lee, Y. N., & Bieniasz, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030010 · Cited by 311
No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
van Dorp, L., Richard, D., Tan, C. C. S., Shaw, L. P., Acman, M., & Balloux, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19818-2 · Cited by 311
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif)
Schröfelbauer, B., Chen, D., & Landau, N. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307132101 · Cited by 309
The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity
Kao, S., Khan, M. A., Miyagi, E., Plishka, R. J., Buckler-White, A. J., & Strebel, K. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11398-11407.2003 · Cited by 309
Complementary function of the two catalytic domains of APOBEC3G
Navarro, F., Bollman, B., Chen, H., König, R., Yu, Q., Chiles, K., & Landau, N. R. (2005) · Virology · doi:10.1016/j.virol.2005.01.011 · Cited by 308
APOBEC3F Can Inhibit the Accumulation of HIV-1 Reverse Transcription Products in the Absence of Hypermutation
Holmes, R. K., Koning, F. A., Bishop, K. N., & Malim, M. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607298200 · Cited by 306
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo
Suspène, R., Guétard, D., Henry, M., Sommer, P., Wain–Hobson, S., & Vartanian, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408223102 · Cited by 305
APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA
Chelico, L., Pham, P., Calabrese, P. P., & Goodman, M. F. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1086 · Cited by 305
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteinesPreprint
Yu, Y., Xiao, Z., Ehrlich, E. S., Yu, X., & Yu, X.-F. (2004) · Genes & Development · doi:10.1101/gad.1250204 · Cited by 305
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor
Bogerd, H. P., Doehle, B., Wiegand, H. L., & Cullen, B. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307713101 · Cited by 295
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradationPreprint
Mehle, A., Gonçalves, J., Santa‐Marta, M., McPike, M. P., & Gabuzda, D. H. (2004) · Genes & Development · doi:10.1101/gad.1249904 · Cited by 294
Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination
Bishop, K. N., Holmes, R. K., & Malim, M. H. (2006) · Journal of Virology · doi:10.1128/jvi.00839-06 · Cited by 292
APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication
Yu, Q., Chen, D., König, R., Mariani, R., Unutmaz, D., & Landau, N. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408802200 · Cited by 290
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti–HIV-1 activity
Peng, G., Lei, K. J., Jin, W., Greenwell‐Wild, T., & Wahl, S. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051512 · Cited by 299
HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis
Mirabello, L. J., Yeager, M., Yu, K. F., Clifford, G. M., Xiao, Y., Zhu, B., Cullen, M., Boland, J. F., Wentzensen, N., Nelson, C. W., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.001 · Cited by 294
Isolation and Characterization of Replication-Competent Human Immunodeficiency Virus Type 1 from a Subset of Elite Suppressors
Blankson, J. N., Bailey, J. R., Thayil, S. M., Yang, H., Lassen, K. G., Lai, J., Gandhi, S. K., Siliciano, J. D., Williams, T. M., & Siliciano, R. F. (2006) · Journal of Virology · doi:10.1128/jvi.02165-06 · Cited by 288
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Coiras, M., López‐Huertas, M. R., Pérez‐Olmeda, M., & Alcamı́, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2223 · Cited by 300
Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination in Viral Infection
Isaacson, M. K., & Ploegh, H. L. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.05.012 · Cited by 285
Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations
Bailey, J. R., Williams, T. M., Siliciano, R. F., & Blankson, J. N. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052319 · Cited by 281
The Restriction Factors of Human Immunodeficiency Virus
Harris, R. S., Hultquist, J. F., & Evans, D. T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.416925 · Cited by 306
Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors
Cullen, B. R. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1067-1076.2006 · Cited by 280
APOBEC-mediated viral restriction: not simply editing?
Holmes, R. K., Malim, M. H., & Bishop, K. N. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.01.004 · Cited by 278
APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles
Zennou, V., Pérez-Caballero, D., Göttlinger, H. G., & Bieniasz, P. D. (2004) · Journal of Virology · doi:10.1128/jvi.78.21.12058-12061.2004 · Cited by 278
Macrophages and their relevance in Human Immunodeficiency Virus Type I infection
Koppensteiner, H., Brack‐Werner, R., & Schindler, M. (2012) · Retrovirology · doi:10.1186/1742-4690-9-82 · Cited by 305
Mammalian transposable elements and their impacts on genome evolution
Platt, R. N., Vandewege, M. W., & Ray, D. A. (2018) · Chromosome Research · doi:10.1007/s10577-017-9570-z · Cited by 291
APOBEC3B and APOBEC3F Inhibit L1 Retrotransposition by a DNA Deamination-independent Mechanism
Stenglein, M. D., & Harris, R. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602367200 · Cited by 277
APOBEC proteins and intrinsic resistance to HIV-1 infection
Malim, M. H. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0185 · Cited by 276
Antiviral Protein APOBEC3G Localizes to Ribonucleoprotein Complexes Found in P Bodies and Stress Granules
Gallois‐Montbrun, S., Kramer, B., Swanson, C. M., Byers, H. L., Lynham, S., Ward, M. A., & Malim, M. H. (2006) · Journal of Virology · doi:10.1128/jvi.02287-06 · Cited by 279
Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration
Mbisa, J. L., Barr, R., Thomas, J. A., Vandegraaff, N., Dorweiler, I. J., Svarovskaia, E. S., Brown, W. L., Mansky, L. M., Gorelick, R. J., Harris, R. S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00272-07 · Cited by 273
Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories
Simmonds, P. (2020) · mSphere · doi:10.1128/msphere.00408-20 · Cited by 245
C-Terminal Deletion of AID Uncouples Class Switch Recombination from Somatic Hypermutation and Gene Conversion
Barreto, V. M., Reina‐San‐Martin, B., Ramiro, A. R., McBride, K. M., & Nussenzweig, M. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00309-5 · Cited by 270
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells
Bogerd, H. P. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj416 · Cited by 270
Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs
Svarovskaia, E. S., Xu, H., Mbisa, J. L., Barr, R., Gorelick, R. J., Ono, A., Freed, E. O., Hu, W.-S., & Pathak, V. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405761200 · Cited by 267
Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication
Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G., & Hughes, S. H. (2010) · Journal of Virology · doi:10.1128/jvi.00915-10 · Cited by 283
Intrinsic host restrictions to HIV-1 and mechanisms of viral escape
Simon, V. R., Bloch, N., & Landau, N. R. (2015) · Nature Immunology · doi:10.1038/ni.3156 · Cited by 273
Going Wild: Lessons from Naturally Occurring T-Lymphotropic Lentiviruses
VandeWoude, S., & Apetrei, C. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-06 · Cited by 262
The Developmental Control of Transposable Elements and the Evolution of Higher Species
Friedli, M., & Trono, D. (2015) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125514 · Cited by 274
Self-citation
The Evolution of Endogenous Viral Elements
Holmes, E. C. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.09.002 · Cited by 266
Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family
Dang, Y., Wang, X., Esselman, W. J., & Zheng, Y. (2006) · Journal of Virology · doi:10.1128/jvi.01123-06 · Cited by 255
Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination
Pecori, R., Giorgio, S. D., Lorenzo, J. P., & Papavasiliou, F. N. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00459-8 · Cited by 262
Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication†
Bonvin, M., Achermann, F., Greeve, I., Stroka, D., Keogh, A., Inderbitzin, D., Candinas, D., Sommer, P., Wain–Hobson, S., Vartanian, J., et al. (2006) · Hepatology · doi:10.1002/hep.21187 · Cited by 252
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition
Chiu, Y., Witkowska, H. E., Hall, S. C., Santiago, M. L., Soros, V. B., Esnault, C., Heidmann, T., & Greene, W. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604524103 · Cited by 244
Human Tripartite Motif 5α Domains Responsible for Retrovirus Restriction Activity and Specificity
Pérez-Caballero, D., Hatziioannou, T., Yang, A., Cowan, S., & Bieniasz, P. D. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.8969-8978.2005 · Cited by 244
The Interaction between HIV-1 Gag and APOBEC3G
Cen, S., Guo, F., Niu, M., Saadatmand, J., Deflassieux, J., & Kleiman, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402062200 · Cited by 242
APOBEC3G Is Incorporated into Virus-like Particles by a Direct Interaction with HIV-1 Gag Nucleocapsid Protein
Alce, T. M., & Popik, W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400235200 · Cited by 239
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion
氏家, 和., 石丸, 健., Barr, R., Zhang, Y., Khan, M. A., Strebel, K., & Pathak, V. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400830101 · Cited by 238
A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action
Mangeat, B., Turelli, P., Liao, S., & Trono, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400060200 · Cited by 237
Self-citation
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif
Doehle, B., Schäfer, A., & Cullen, B. R. (2005) · Virology · doi:10.1016/j.virol.2005.06.005 · Cited by 227
Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation
Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J. C., & Yu, X.-F. (2007) · Journal of Virology · doi:10.1128/jvi.02584-06 · Cited by 224
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor
Schäfer, A., Bogerd, H. P., & Cullen, B. R. (2004) · Virology · doi:10.1016/j.virol.2004.08.006 · Cited by 223
Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome
Bárbaro, G., Scozzafava, A., Mastrolorenzo, A., & Supuran, C. T. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764869 · Cited by 222
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G
Chen, K., Harjes, E., Gross, P. J., Fahmy, A., Lu, Y., Shindo, K., Harris, R. S., & Matsuo, H. (2008) · Nature · doi:10.1038/nature06638 · Cited by 218

Authors: Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., & Trono, D.
Affiliations: University of Geneva (CH)
Corresponding author: Trono, Didier
ORCID: Mangeat, Bastien
Turelli, Priscilla
Caron, Gersende
Trono, Didier
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2003-05-28
Volume: 424
Issue: 6944
Pages: 99-103
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature01709
OpenAlex: W1966343819
Cited by: 1,486
References: 28
Citations by year: 2026: 20 · 2025: 29 · 2024: 23 · 2023: 28 · 2022: 25 · 2021: 43 · 2020: 37 · 2019: 53 · 2018: 49 · 2017: 56 · 2016: 58 · 2015: 58 · 2014: 79 · 2013: 87 · 2012: 97
FWCI: 36.98
Type: journal article
Language: en
Open access: green
infoscience.epfl.ch
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Topics: Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords: APOBEC3G, HIV-1 Vif, APOBEC1, cytosine deamination, reverse transcription, G-to-A hypermutation, retrovirus restriction, T cells, RNA editing
MeSH terms: APOBEC-3G Deaminase, Antiviral Agents, Base Sequence, Cell Line, Cytidine Deaminase, DNA, Viral, Humans, Molecular Sequence Data, Nucleoside Deaminases, Proteins, Repressor Proteins, RNA, Messenger, Transcription, Genetic, Virus Replication, HIV-1, Mutagenesis, Gene Products, vif, Point Mutation, RNA Editing, Viral Load, vif Gene Products, Human Immunodeficiency Virus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks